🇺🇸 Buffered Lidocaine in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Triglycerides Increased — 2 reports (16.67%)
  2. Lymphocyte Count Decreased — 2 reports (16.67%)
  3. Abdominal Discomfort — 1 report (8.33%)
  4. Angle Closure Glaucoma — 1 report (8.33%)
  5. Blood Glucose Increased — 1 report (8.33%)
  6. Cardiac Disorder — 1 report (8.33%)
  7. Colitis — 1 report (8.33%)
  8. Crohn^S Disease — 1 report (8.33%)
  9. Cystitis — 1 report (8.33%)
  10. Dermatitis — 1 report (8.33%)

Source database →

Other Anesthesia/Pain Management approved in United States

Frequently asked questions

Is Buffered Lidocaine approved in United States?

Buffered Lidocaine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Buffered Lidocaine in United States?

University of California, San Diego is the originator. The local marketing authorisation holder may differ — check the official source linked above.